Skip to main content
Premium Trial:

Request an Annual Quote

Novartis Extends Alnylam RNAi Rx Partnership for Fifth Year


Alnylam Pharmaceuticals last week announced that Novartis has decided to extend the companies' RNAi therapeutics collaboration for a fifth year, the last under the terms of the deal, through October 2010.

The deal was first announced in Sept. 2005, and called for Alnylam to optimize certain of Novartis' lead RNAi drug candidates, which Novartis would develop and commercialize (see RNAi News, 9/9/2005).

The deal had an initial three-year term, but included the option for Novartis to extend it for two additional one-year periods.

In addition to paying Alnylam upfront fees, research funding, and milestones, Novartis purchased what was then 19.9 percent of the RNAi drug shop's equity. That stake currently stands at around 13.4 percent, according to Alnylam.

"We are thrilled that Novartis has once again elected to extend our alliance, this time for a fifth and final planned year," Alnylam CEO John Maraganore said in a statement. "This is the second extension that Novartis has elected to make, which we believe reflects the success of our collaborative efforts as well as the scientific progress we have made in advancing our innovative technology to patients."

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.